3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Transitional Cell
14
Urinary Bladder Neoplasms
13
Colorectal Neoplasms
10
Carcinoma, Merkel Cell
9
Breast Neoplasms
9
Carcinoma, Renal Cell
7
Neoplasms
6
Neoplasm Metastasis
6
Carcinoma, Non-Small-Cell Lung
6
Small Cell Lung Carcinoma
4
Carcinoma, Hepatocellular
4
Turcot syndrome
3
Stomach Neoplasms
3
Neuroendocrine Tumors
3
Head and Neck Neoplasms
3
Endometrial Neoplasms
3
Urethral Neoplasms
2
Ureteral Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Penile Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Melanoma
2
Lung Neoplasms
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Neuroendocrine
2
Uterine Cervical Neoplasms
1
Interventions
Paclitaxel
6
Doxorubicin
6
Gemcitabine
4
Bevacizumab
4
pembrolizumab
3
pazopanib
3
durvalumab
3
Sorafenib
3
Docetaxel
3
trebananib
2
spartalizumab
2
cemiplimab
2
brostallicin
2
Propranolol
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Imatinib Mesylate
2
Ifosfamide
2
Carboplatin
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
tremelimumab
1
trastuzumab duocarmazine
1
temsirolimus
1
talimogene laherparepvec
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hemangiosarcoma
×
avelumab
×
Clear all
NCT03512834
2018-07-11
ASAP
Dong-A University Hospital
Phase 2
Unknown
32 enrolled